Nijenhuis-Noort , Kirsten A
No regulatory authority Health Canada, the FDA, the EMA, the TGA, or any equivalent has cleared either component peptide, or the blend formulation, as a drug for human or veterinary use
Experimental data suggest that AAS exposure may suppress lymphocyte proliferation and reduce immunoglobulin production, indicating a degree of immunomodulation
Stress Modulation: DSIP may influence the hypothalamic-pituitary-adrenal (HPA) axis, potentially reducing cortisol levels and enhancing stress resilience Recovery and Neuroprotection: Early studies suggest DSIP may support growth hormone release, antioxidant protection, and neuroprotection Pain and Mood: Some experimental data indicate potential benefits in pain relief and mood stabilization
Semax and Selank have a real, if mostly Russian, clinical research history